Aureka Biotechnologies, an AI-native TechBio company, announced on Monday the close of a USD100m Series B financing.

Granite Asia funded the first tranche exclusively, and a prominent strategic investor led a subsequent tranche, with participation from HighLight Capital (HLC) and follow-on investment from existing shareholders including MPCi and NRL Capital. Aureka has now raised nearly USD200m to date.

The company intends to direct proceeds primarily toward research and large-scale training of its next generation of biological foundation models, further strengthening performance on core tasks such as de novo molecular design, biological structure modelling and function prediction.

Aureka will also upgrade Lab-in-the-Loop, its experiment-centred feedback engine, strengthening the closed-loop between those models and its proprietary single-cell functional screening, high-throughput experimental validation and drug development platforms.

With its closed-loop, AI-native infrastructure already built, Aureka says that it is now strengthening the intelligence core of that system: its foundation models. Aureka combines large-scale pre-training, project-specific post-training, AI agents and experiments that run at scale into AI-for-Science infrastructure for the life sciences. In it, models do not just solve individual drug discovery tasks; they learn the rules of biology, to understand, generate, predict and intervene in complex biological systems.

As foundation models and automated R&D converge, Aureka is transitioning from using AI to make drug discovery more efficient, to using AI to model living systems.